



Company Announcement

Nykode Therapeutics (formerly Vaccibody*) resolves to issue shares to Regeneron

Oslo, Norway, November 24, 2021 – Nykode Therapeutics (formerly Vaccibody*) (Euronext Growth (Oslo): VACC) refers to the announcement made on November 23, 2021 regarding the execution of a multi-target license and collaboration agreement with Regeneron.

In accordance with the agreement and as described in the initial announcement, the board of directors of Nykode Therapeutics has today resolved to issue 2,255,034 new shares to Regeneron at a price of NOK 79.07 per share, based on a resolution to increase the share capital granted by the annual general meeting on May 5, 2021.

Following registration of the share capital increase related to the share issue, the share capital of Nykode Therapeutics will be NOK 2,895,027.44, divided into 289,502,744 shares, each with a par value of NOK 0.01.

*) Vaccibody AS, which is changing its company name to Nykode Therapeutics AS, has called for an EGM on November 30, 2021, to vote for the approval of the change of its company name from Vaccibody AS to Nykode Therapeutics AS.

About Nykode Therapeutics*)

Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and infectious diseases. Nykode Therapeutics' modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.

Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumours and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.



The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and collaborate with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics' shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC (ticker will soon be changed). Further information about Nykode Therapeutics may be found at <http://www.nykode.com>

Contact for Nykode Therapeutics AS*):

CFO Harald Gurvin
Nykode Therapeutics AS
ir@nykode.com

Nykode Therapeutics AS*)

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.